Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ferrarini, Marina ^a   Steimberg, Nathalie ^b   Ponzoni, Maurilio ^a   Belloni, Daniela ^a   Berenzi, Angiola ^b   Girlanda, Stefania ^a   Caligaris Cappio, Federico ^a,c   Mazzoleni, Giovanna ^b   Ferrero, Elisabetta ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GELATINASE A; GELATINASE B; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOREACTOR; BONE MARROW BIOPSY; CANCER PATIENT; CANCER RESEARCH; CANCER TISSUE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; EX VIVO STUDY; EXPLANT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN ANALYSIS; RAT; ROTARY CELL CULTURE SYSTEM BIOREACTOR; SUPERNATANT; THREE DIMENSIONAL CULTURE; TISSUE CULTURE TECHNIQUE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VALIDATION PROCESS;

ADULT; AGED; ANGIOPOIETIN-2; ANIMALS; BETA 2-MICROGLOBULIN; BIOREACTORS; BONE AND BONES; BONE MARROW CELLS; BORONIC ACIDS; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME INHIBITORS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883190440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071613     Document Type: Article

References (49)

1. Hallek M, Bergsagel PL, Anderson KC, (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21.
2. Hussein MA, Juturi JV, Lieberman I, (2002) Multiple myeloma: present and future. Curr Opin Oncol 14: 31-35.
3. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
4. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F, (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367-3375.
5. Tlsty TD, Coussens LM, (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-150.
6. Hu M, Polyak K, (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27-34.
7. Pampaloni F, Reynaud EG, Stelzer EH, (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845.
8. Yamada M, Cukierman E, (2007) Modeling Tissue Morphogenesis and Cancer in 3D K. Cell 130: 601-610.
9. Mazzoleni G, Di Lorenzo D, Steimberg N, (2009) Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? Genes Nutr 4: 13-22.
10. Mazzoleni G, Steimberg N, (2010) 3D culture in microgravity: a realistic alternative to experimental animal use. ALTEX 27: 321-324.
11. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, et al. (2007) Engineering tumors with 3D scaffolds. Nat Methods 4: 855-860.
12. Lee GY, Kenny PA, Lee EH, Bissell MJ, (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365.
13. Mastro AM, Vogler EA, (2009) A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res 69: 4097-4100.
14. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, et al. (2008) A unique three-dimensional model for evaluating the impact of therapy on Multiple Myeloma. Blood 112: 2935-2945.
15. Vacca A, Ribatti D, (2006) Bone Marrow angiogenesis in Multiple Myeloma. Leukemia 20: 193-199.
16. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, et al. (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114: 123-148.
17. Storti P, Donofrio G, Colla S Airoldi I, Bolzoni M, et al. (2011) HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 25: 527-537.
18. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E, (2008) Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 49: 677-689.
19. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, et al. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66: 184-191.
20. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, et al. (2007) Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109: 2565-2570.
21. Belloni D, Veschini L, Foglieni C Dell'Antonio G, Caligaris-Cappio F, et al. (2010) Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res 316: 1010-1018.
22. Ferrarini M, Ferrero E, (2011) Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. Curr Med Chem 18: 5185-5195.
23. Vickers AE, Fisher RL, (2004) Organ slices for the evaluation of human drug toxicity. Chemico-Biological Interactions 50: 87-96.
24. Cosmi F, Steimberg N, Dreossi D, Mazzoleni G, (2009) Structural analysis of rat bone explants kept in vitro in simulated microgravity conditions. J Mech Behav Biomed Mater 2: 164-172.
25. Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, et al. (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118: 817-820.
26. Veschini L, Crippa L, Dondossola E, Doglioni C, Corti A, et al. (2011) The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J 25: 3906-3914.
27. Zdzisińska B, Walter-Croneck A, Kandefer-Szerszeń M, (2008) Matrix metalloproteinases-1 and-2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients. Leuk Res 32: 1763-1769.
28. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, et al. (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 65: 7502-7508.
29. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R, (2008) Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol 141: 494-503.
30. Zocchi MR, Ferrero E, Leone BE, Rovere P, Bianchi E, et al. (1996) CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Eur J Immunol 26: 759-767.
31. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
32. Tsirakis G, Pappa CA, Kaparou M, Katsomitrou V, Hatzivasili A, et al. (2011) Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients. Eur J Histochem 55: e21.
33. Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, et al. (2012) Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 1;130: 735-742.
34. Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L, et al. (2001) Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol 106: 62-69.
35. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC, (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 101: 950-968.
36. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW, (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70: 537-546.
37. van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P, (2007) Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro 21: 545-557.
38. Schumacher K, Khong YM, Chang S, Ni J, Sun W, et al. (2007) Perfusion culture improves the maintenance of cultured liver tissue slices. Tissue Eng 13: 197-205.
39. Mazzoleni G and Steimberg N (2012). New models for the in vitro study of liver toxicity: 3D culture systems and the role of bioreactors. InThe continuum of Health Risk Assessment, M.GTyshenko. ed., Intech Open Access Publisher, Rijeka, Croatia; pp. 161-194.
40. Steimberg N, Boniotti J., Mazzoleni G (2010). 3D culture of primary chondrocytes, cartilage, and bone/cartilage explants in simulated microgravity. In: Methods in Bioengineering: Alternative Technologies to Animal Testing, Maguire and Novak eds., Boston, USA; pp. 205-212,.
41. Becker JL, Souza GR, (2013) Using space-based investigations to inform cancer research on Earth. Nat Rev Cancer 13 (5) (): 315-327.
42. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, et al. (2010) Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24 (11) (): 1967-1970.
43. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, et al. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25: 707-711.
44. Vacca A, Ria R, Semeraro F Merchionne F, Coluccia M, et al. (2003) Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102: 3340-3348.
45. Joshi S, Khan R, Sharma M, Kumar L, Sharma A, (2011) Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin Biochem 44: 590-595.
46. Bolkun L, Lemancewicz D, Sobolewski K, Mantur M, Semeniuk J, et al. (2012) The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Adv Med Sci pp. 18-25.
47. Gumieiro DN, Rafacho BP, Gonçalves AF, Santos PP, Azevedo PS, et al. (2013) Serum metalloproteinases 2 and 9 as predictors of gait status, pressure ulcer and mortality after hip fracture. PLoS One 8 (2) (): e57424.
48. Ferrarini M, Mazzoleni G, Steimberg N, Belloni D, Ferrero E (2013). Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs In: "Multiple Myeloma- A Quick Reflection on the Fast Progress", InTech, Chapter 3, pp.39-60.
49. Rajkumar SV, (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8: 479-491.